The outcome of semaglutide on cardiac repolarization was tested in a radical QTc trial. Semaglutide doesn't prolong QTc intervals at doses approximately one.5 mg at steady-condition. Those with variety 2 diabetic issues and regarded cardiovascular disease are at a higher risk of major cardiovascular situations like stroke, coronary heart assault